It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
(emphasis mine)
This is a confidential pharmaceutical industry trade association dossier about the WHO Expert Working Group (EWG) on R&D Financing.
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA; "Big Pharma") gave its members 4 documents: a non-public draft report of the WHO EWG and a non-public Comparative Analysis done by the working group, the IFPMA Overview of the EWG
Comparative Analysis, and IFPMA summary slide on the EWG Draft Report.
The compilation of documents shows the influence of "Big Pharma" on the policy making decisions of the WHO, the UN body safeguarding public health. These confidential documents were obtained by the drug industry before their public release to WHO member states (scheduled to be released May 2010). The document also illustrates that the WHO expert group was highly responsive to industry lobbying — a result that public health groups had feared since early 2009, when the expert group met with the industry, but refused to meet with public health groups known to be industry critics.
The likely audience for these documents include countries, public health policy makers, civil society, industry, academia, media, patients and the general public.
Originally posted by DevolutionEvolvd
The problem with this is the obvious influence that industry support has on research integrity.